Dynamic landscape of m6A modifications and related post-transcriptional events in muscle-invasive bladder cancer.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 05 08 2024
accepted: 23 09 2024
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

Muscle-invasive bladder carcinoma (MIBC) is a serious and more advanced stage of bladder carcinoma. N6-Methyladenosine (m6A) is a dynamic and reversible modifications that primarily affects RNA stability and alternative splicing. The dysregulation of m6A in MIBC can be potential target for clinical interventions, but there have been limited studies on m6A modifications in MIBC and their associations with post-transcriptional regulatory processes. Paired tumor and adjacent-normal tissues were obtained from three patients with MIBC following radical cystectomy. The additional paired tissues for validation were obtained from patients underwent transurethral resection. Utilizing Nanopore direct-RNA sequencing, we characterized the m6A RNA methylation landscape in MIBC, with a focus on identifying post-transcriptional events potentially affected by changes in m6A sites. This included an examination of differential transcript usage, polyadenylation signal sites, and variations in poly(A) tail length, providing insights into the broader impact of m6A alterations on RNA processing in MIBC. The prognostic-related m6A genes and m6A-risk model constructed by machine learning enables the stratification of high and low-risk patients with precision. A novel m6A modification site in the 3' untranslated region (3'UTR) of IGLL5 gene were identified, characterized by a lower m6A methylation ratio, elongated poly(A) tails, and a notable bias in transcript usage. Furthermore, we discovered two particular transcripts, VWA1-203 and CEBPB-201. VWA1-203 displayed diminished m6A methylation levels, a truncated 3'UTR, and an elongated poly(A) tail, whereas CEBPB-201 showed opposite trends, highlighting the complex interplay between m6A modifications and RNA processing. Source code was provided on GitHub ( https://github.com/lelelililele/Nanopore-m6A-analysis ). The state-of-the-art Nanopore direct-RNA sequencing and machine learning techniques enables comprehensive identification of m6A modification and provided insights into the potential post-transcriptional regulation mechanisms on the development and progression in MIBC.

Sections du résumé

BACKGROUND BACKGROUND
Muscle-invasive bladder carcinoma (MIBC) is a serious and more advanced stage of bladder carcinoma. N6-Methyladenosine (m6A) is a dynamic and reversible modifications that primarily affects RNA stability and alternative splicing. The dysregulation of m6A in MIBC can be potential target for clinical interventions, but there have been limited studies on m6A modifications in MIBC and their associations with post-transcriptional regulatory processes.
METHODS METHODS
Paired tumor and adjacent-normal tissues were obtained from three patients with MIBC following radical cystectomy. The additional paired tissues for validation were obtained from patients underwent transurethral resection. Utilizing Nanopore direct-RNA sequencing, we characterized the m6A RNA methylation landscape in MIBC, with a focus on identifying post-transcriptional events potentially affected by changes in m6A sites. This included an examination of differential transcript usage, polyadenylation signal sites, and variations in poly(A) tail length, providing insights into the broader impact of m6A alterations on RNA processing in MIBC.
RESULTS RESULTS
The prognostic-related m6A genes and m6A-risk model constructed by machine learning enables the stratification of high and low-risk patients with precision. A novel m6A modification site in the 3' untranslated region (3'UTR) of IGLL5 gene were identified, characterized by a lower m6A methylation ratio, elongated poly(A) tails, and a notable bias in transcript usage. Furthermore, we discovered two particular transcripts, VWA1-203 and CEBPB-201. VWA1-203 displayed diminished m6A methylation levels, a truncated 3'UTR, and an elongated poly(A) tail, whereas CEBPB-201 showed opposite trends, highlighting the complex interplay between m6A modifications and RNA processing. Source code was provided on GitHub ( https://github.com/lelelililele/Nanopore-m6A-analysis ).
CONCLUSIONS CONCLUSIONS
The state-of-the-art Nanopore direct-RNA sequencing and machine learning techniques enables comprehensive identification of m6A modification and provided insights into the potential post-transcriptional regulation mechanisms on the development and progression in MIBC.

Identifiants

pubmed: 39380003
doi: 10.1186/s12967-024-05701-x
pii: 10.1186/s12967-024-05701-x
doi:

Substances chimiques

Adenosine K72T3FS567
N-methyladenosine CLE6G00625
RNA, Messenger 0
3' Untranslated Regions 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

912

Subventions

Organisme : Bethune Charitable Foundation
ID : mnzl202009
Organisme : National High Level Hospital Clinical Research Funding
ID : BJ-2022-144
Organisme : National High Level Hospital Clinical Research Funding
ID : BJ-2022-174
Organisme : National High Level Hospital Clinical Research Funding
ID : BJ-2023-198
Organisme : National High Level Hospital Clinical Research Funding
ID : BJ-2024-153

Informations de copyright

© 2024. The Author(s).

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
pubmed: 30207593 doi: 10.3322/caac.21492
Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat Reviews Disease Primers. 2017;3:17022.
pubmed: 28406148 doi: 10.1038/nrdp.2017.22
Zhang L, Li Y, Zhou L, Zhou H, Ye L, Ou T, et al. The m6A reader YTHDF2 promotes bladder Cancer progression by suppressing RIG-I-Mediated Immune Response. Cancer Res. 2023;83(11):1834–50.
pubmed: 36939388 pmcid: 10236158 doi: 10.1158/0008-5472.CAN-22-2485
Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncology: Official J Am Soc Clin Oncol. 2002;20(14):3061–71.
doi: 10.1200/JCO.2002.11.027
Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.
pubmed: 24373477 doi: 10.1016/j.eururo.2013.11.046
Nombela P, Miguel-López B, Blanco S. The role of m(6)A, m(5)C and Ψ RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer. 2021;20(1):18.
pubmed: 33461542 pmcid: 7812662 doi: 10.1186/s12943-020-01263-w
Adhikari S, Xiao W, Zhao YL, Yang YG. M(6)A: signaling for mRNA splicing. RNA Biol. 2016;13(9):756–9.
pubmed: 27351695 pmcid: 5013988 doi: 10.1080/15476286.2016.1201628
Lesbirel S, Wilson SA. The m(6)A–methylase complex and mRNA export. Biochim et Biophys acta Gene Regul Mech. 2019;1862(3):319–28.
doi: 10.1016/j.bbagrm.2018.09.008
Mao Y, Dong L, Liu XM, Guo J, Ma H, Shen B, et al. M(6)A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2. Nat Commun. 2019;10(1):5332.
pubmed: 31767846 pmcid: 6877647 doi: 10.1038/s41467-019-13317-9
Rücklé C, Körtel N, Basilicata MF, Busch A, Zhou Y, Hoch-Kraft P, et al. RNA stability controlled by m(6)a methylation contributes to x-to-autosome dosage compensation in mammals. Nat Struct Mol Biol. 2023;30(8):1207–15.
pubmed: 37202476 pmcid: 10442230 doi: 10.1038/s41594-023-00997-7
Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Therapy. 2021;6(1):74.
doi: 10.1038/s41392-020-00450-x
An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21(1):14.
pubmed: 35022030 pmcid: 8753874 doi: 10.1186/s12943-022-01500-4
Zhuang C, Zhuang C, Luo X, Huang X, Yao L, Li J, et al. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis. J Cell Mol Med. 2019;23(3):2163–73.
pubmed: 30648791 pmcid: 6378205 doi: 10.1111/jcmm.14128
Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020;39(23):4507–18.
pubmed: 32366907 doi: 10.1038/s41388-020-1303-7
He Y, Yue H, Cheng Y, Ding Z, Xu Z, Lv C, et al. ALKBH5-mediated m(6)a demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis. 2021;12(12):1121.
pubmed: 34853296 pmcid: 8636648 doi: 10.1038/s41419-021-04401-4
Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, et al. M(6)a mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20(9):1074–83.
pubmed: 30154548 pmcid: 6245953 doi: 10.1038/s41556-018-0174-4
Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2019;442:252–61.
pubmed: 30423408 doi: 10.1016/j.canlet.2018.11.006
Gao Q, Zheng J, Ni Z, Sun P, Yang C, Cheng M, et al. The m(6)a methylation-regulated AFF4 promotes Self-Renewal of bladder Cancer stem cells. Stem Cells Int. 2020;2020:8849218.
pubmed: 32676121 pmcid: 7352121 doi: 10.1155/2020/8849218
Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W, et al. RNA m(6)a methylation regulates the ultraviolet-induced DNA damage response. Nature. 2017;543(7646):573–6.
pubmed: 28297716 pmcid: 5490984 doi: 10.1038/nature21671
Shen S, Zhang R, Jiang Y, Li Y, Lin L, Liu Z, et al. Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types. Mol Cancer. 2021;20(1):67.
pubmed: 33849552 pmcid: 8045265 doi: 10.1186/s12943-021-01362-2
Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, et al. Nuclear m(6)a reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61(4):507–19.
pubmed: 26876937 doi: 10.1016/j.molcel.2016.01.012
Mendel M, Delaney K, Pandey RR, Chen KM, Wenda JM, Vågbø CB, et al. Splice site m(6)a methylation prevents binding of U2AF35 to inhibit RNA splicing. Cell. 2021;184(12):3125–e4225.
pubmed: 33930289 pmcid: 8208822 doi: 10.1016/j.cell.2021.03.062
Chen L, Fu Y, Hu Z, Deng K, Song Z, Liu S, et al. Nuclear m(6) a reader YTHDC1 suppresses proximal alternative polyadenylation sites by interfering with the 3’ processing machinery. EMBO Rep. 2022;23(11):e54686.
pubmed: 36094741 pmcid: 9638877 doi: 10.15252/embr.202254686
Beisang D, Bohjanen PR. Perspectives on the ARE as it turns 25 years old. Wiley Interdisciplinary Reviews RNA. 2012;3(5):719–31.
pubmed: 22733578 pmcid: 4126804 doi: 10.1002/wrna.1125
Guo S, Lin S. mRNA alternative polyadenylation (APA) in regulation of gene expression and diseases. Genes Dis. 2023;10(1):165–74.
pubmed: 37013028 doi: 10.1016/j.gendis.2021.09.005
Ha KCH, Blencowe BJ, Morris Q. QAPA: a new method for the systematic analysis of alternative polyadenylation from RNA-seq data. Genome Biol. 2018;19(1):45.
pubmed: 29592814 pmcid: 5874996 doi: 10.1186/s13059-018-1414-4
Slobodin B, Bahat A, Sehrawat U, Becker-Herman S, Zuckerman B, Weiss AN, et al. Transcription Dynamics regulate poly(A) tails and expression of the RNA degradation Machinery to Balance mRNA levels. Mol Cell. 2020;78(3):434–e445.
pubmed: 32294471 doi: 10.1016/j.molcel.2020.03.022
Jalkanen AL, Coleman SJ, Wilusz J. Determinants and implications of mRNA poly(A) tail size–does this protein make my tail look big? Semin Cell Dev Biol. 2014;34:24–32.
pubmed: 24910447 doi: 10.1016/j.semcdb.2014.05.018
Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149(7):1635–46.
pubmed: 22608085 pmcid: 3383396 doi: 10.1016/j.cell.2012.05.003
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–6.
pubmed: 22575960 doi: 10.1038/nature11112
Imamachi N, Salam KA, Suzuki Y, Akimitsu N. A GC-rich sequence feature in the 3’ UTR directs UPF1-dependent mRNA decay in mammalian cells. Genome Res. 2017;27(3):407–18.
pubmed: 27940950 pmcid: 5340968 doi: 10.1101/gr.206060.116
Zhang L, Kasif S, Cantor CR, Broude NE. GC/AT-content spikes as genomic punctuation marks. Proc Natl Acad Sci U S A. 2004;101(48):16855–60.
pubmed: 15548610 pmcid: 534751 doi: 10.1073/pnas.0407821101
Deamer D, Akeson M, Branton D. Three decades of nanopore sequencing. Nat Biotechnol. 2016;34(5):518–24.
pubmed: 27153285 pmcid: 6733523 doi: 10.1038/nbt.3423
Jain M, Olsen HE, Paten B, Akeson M. The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol. 2016;17(1):239.
pmcid: 5124260 doi: 10.1186/s13059-016-1103-0
Tyler AD, Mataseje L, Urfano CJ, Schmidt L, Antonation KS, Mulvey MR, et al. Evaluation of Oxford Nanopore’s MinION sequencing device for Microbial whole genome sequencing applications. Sci Rep. 2018;8(1):10931.
pubmed: 30026559 pmcid: 6053456 doi: 10.1038/s41598-018-29334-5
Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford Nanopore sequencing. Genome Biol. 2019;20(1):129.
pubmed: 31234903 pmcid: 6591954 doi: 10.1186/s13059-019-1727-y
Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34(18):3094–100.
pubmed: 29750242 pmcid: 6137996 doi: 10.1093/bioinformatics/bty191
Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland JE, Mudge JM, et al. GENCODE 2021. Nucleic Acids Res. 2021;49(D1):D916–23.
pubmed: 33270111 doi: 10.1093/nar/gkaa1087
Qin H, Ou L, Gao J, Chen L, Wang JW, Hao P, et al. DENA: training an authentic neural network model using Nanopore sequencing data of Arabidopsis transcripts for detection and quantification of N(6)-methyladenosine on RNA. Genome Biol. 2022;23(1):25.
pubmed: 35039061 pmcid: 8762864 doi: 10.1186/s13059-021-02598-3
Pratanwanich PN, Yao F, Chen Y, Koh CWQ, Wan YK, Hendra C, et al. Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore. Nat Biotechnol. 2021;39(11):1394–402.
pubmed: 34282325 doi: 10.1038/s41587-021-00949-w
Hendra C, Pratanwanich PN, Wan YK, Goh WSS, Thiery A, Göke J. Detection of m6A from direct RNA sequencing using a multiple instance learning framework. Nat Methods. 2022;19(12):1590–8.
pubmed: 36357692 pmcid: 9718678 doi: 10.1038/s41592-022-01666-1
Gleeson J, Leger A, Prawer YDJ, Lane TA, Harrison PJ, Haerty W, et al. Accurate expression quantification from nanopore direct RNA sequencing with NanoCount. Nucleic Acids Res. 2022;50(4):e19.
pubmed: 34850115 doi: 10.1093/nar/gkab1129
Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417–9.
pubmed: 28263959 pmcid: 5600148 doi: 10.1038/nmeth.4197
Tekath T, Dugas M. Differential transcript usage analysis of bulk and single-cell RNA-seq data with DTUrtle. Bioinformatics. 2021;37(21):3781–7.
pubmed: 34469510 pmcid: 8570804 doi: 10.1093/bioinformatics/btab629
Hao Z, Lv D, Ge Y, Shi J, Weijers D, Yu G, et al. RIdeogram: drawing SVG graphics to visualize and map genome-wide data on the idiograms. PeerJ Comput Sci. 2020;6:e251.
pubmed: 33816903 pmcid: 7924719 doi: 10.7717/peerj-cs.251
Loman NJ, Quick J, Simpson JT. A complete bacterial genome assembled de novo using only nanopore sequencing data. Nat Methods. 2015;12(8):733–5.
pubmed: 26076426 doi: 10.1038/nmeth.3444
Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–31.
pubmed: 31504780 doi: 10.1093/nar/gkz757
Gustavsson EK, Zhang D, Reynolds RH, Garcia-Ruiz S, Ryten M. Ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2. Bioinformatics. 2022;38(15):3844–6.
pubmed: 35751589 pmcid: 9344834 doi: 10.1093/bioinformatics/btac409
McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28(5):495–501.
pubmed: 20436461 pmcid: 4840234 doi: 10.1038/nbt.1630
Tanigawa Y, Dyer ES, Bejerano G. WhichTF is functionally important in your open chromatin data? PLoS Comput Biol. 2022;18(8):e1010378.
pubmed: 36040971 pmcid: 9426921 doi: 10.1371/journal.pcbi.1010378
Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50(D1):D165–73.
pubmed: 34850907 doi: 10.1093/nar/gkab1113
Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32(Database issue):D91–4.
pubmed: 14681366 pmcid: 308747 doi: 10.1093/nar/gkh012
Paz I, Kosti I, Ares M Jr., Cline M, Mandel-Gutfreund Y. RBPmap: a web server for mapping binding sites of RNA-binding proteins. Nucleic Acids Res. 2014;42(Web Server issue):W361–7.
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8.
pubmed: 32444850 pmcid: 7386072 doi: 10.1038/s41587-020-0546-8
Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox’s proportional hazards Model via Coordinate Descent. J Stat Softw. 2011;39(5):1–13.
pubmed: 27065756 pmcid: 4824408 doi: 10.18637/jss.v039.i05
Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
pubmed: 21414208 pmcid: 3068975 doi: 10.1186/1471-2105-12-77
Castellanos-Rubio A, Santin I, Olazagoitia-Garmendia A, Romero-Garmendia I, Jauregi-Miguel A, Legarda M, et al. A novel RT-QPCR-based assay for the relative quantification of residue specific m6A RNA methylation. Sci Rep. 2019;9(1):4220.
pubmed: 30862814 pmcid: 6414506 doi: 10.1038/s41598-019-40018-6
Sathe A, Nawroth R. Targeting the PI3K/AKT/mTOR pathway in bladder Cancer. Methods Mol Biol. 2018;1655:335–50.
pubmed: 28889395 doi: 10.1007/978-1-4939-7234-0_23
Majid S, Saini S, Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer. 2012;11:7.
pubmed: 22325146 pmcid: 3293036 doi: 10.1186/1476-4598-11-7
Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328(2):198–206.
pubmed: 23022474 doi: 10.1016/j.canlet.2012.09.017
Feng Y, Zhang T, Wang Y, Xie M, Ji X, Luo X, et al. Homeobox genes in cancers: from carcinogenesis to recent therapeutic intervention. Front Oncol. 2021;11:770428.
pubmed: 34722321 pmcid: 8551923 doi: 10.3389/fonc.2021.770428
Xia ZN, Wang XY, Cai LC, Jian WG, Zhang C. IGLL5 is correlated with tumor-infiltrating immune cells in clear cell renal cell carcinoma. FEBS open bio. 2021;11(3):898–910.
pubmed: 33449444 pmcid: 7931224 doi: 10.1002/2211-5463.13085
Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, et al. VIRMA mediates preferential m(6)a mRNA methylation in 3’UTR and near stop codon and associates with alternative polyadenylation. Cell Discovery. 2018;4:10.
pubmed: 29507755 pmcid: 5826926 doi: 10.1038/s41421-018-0019-0
Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D. Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res. 2013;19(11):2850–60.
pubmed: 23575475 pmcid: 3695228 doi: 10.1158/1078-0432.CCR-12-3084
Liang L, Zhao K, Zhu JH, Chen G, Qin XG, Chen JQ. Comprehensive evaluation of FKBP10 expression and its prognostic potential in gastric cancer. Oncol Rep. 2019;42(2):615–28.
pubmed: 31233188 pmcid: 6609316
Shabek N, Ruble J, Waston CJ, Garbutt KC, Hinds TR, Li T, et al. Structural insights into DDA1 function as a core component of the CRL4-DDB1 ubiquitin ligase. Cell Discovery. 2018;4:67.
pubmed: 30564455 pmcid: 6288126 doi: 10.1038/s41421-018-0064-8
Liu K, Chen Y, Li B, Li Y, Liang X, Lin H et al. Upregulation of apolipoprotein L6 improves Tumor Immunotherapy by Inducing Immunogenic Cell Death. Biomolecules. 2023;13(3).
Liu S, Shi J, Wang L, Huang Y, Zhao B, Ding H, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med. 2022;189:42–57.
pubmed: 35850179 doi: 10.1016/j.freeradbiomed.2022.06.247
Cano CE, Pasero C, De Gassart A, Kerneur C, Gabriac M, Fullana M, et al. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells. Cell Rep. 2021;36(2):109359.
pubmed: 34260935 doi: 10.1016/j.celrep.2021.109359
Velusamy T, Palanisamy N, Kalyana-Sundaram S, Sahasrabuddhe AA, Maher CA, Robinson DR, et al. Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2013;110(8):3035–40.
pubmed: 23382248 pmcid: 3581970 doi: 10.1073/pnas.1214326110
Wang L, Zhang Z, Zhou X, Wu J, Hong Z. Comprehensive analysis of the expression and prognosis of YPEL family members in clear cell renal cell cancer. Oncol Rep. 2022;48(1).
Hong D, Jeong S. 3’UTR diversity: expanding repertoire of RNA alterations in human mRNAs. Mol Cells. 2023;46(1):48–56.
pubmed: 36697237 pmcid: 9880603 doi: 10.14348/molcells.2023.0003
Xiang K, Bartel DP. The molecular basis of coupling between poly(A)-tail length and translational efficiency. Elife. 2021;10.

Auteurs

Lili Zhang (L)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Ziwei Chen (Z)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Gaoyuan Sun (G)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Chang Li (C)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Pengjie Wu (P)

Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Wenrui Xu (W)

Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.

Hui Zhu (H)

Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing, China.

Zaifeng Zhang (Z)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Yongbin Tang (Y)

Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Yayu Li (Y)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
University of Chinese Academy of Sciences Medical School, Beijing, China.

Yifei Li (Y)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Siyuan Xu (S)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Hexin Li (H)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Meng Chen (M)

National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Fei Xiao (F)

Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. xiaofei3965@bjhmoh.cn.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. xiaofei3965@bjhmoh.cn.

Yaqun Zhang (Y)

Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. zhangyaqun@yeah.net.

Wei Zhang (W)

Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. zwigyl@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH